Benzinga | Feb 24, 2021 04:05PM EST

Fate Therapeutics Q4 EPS $(0.61) Misses $(0.39) Estimate, Sales $15.90M May Not Compare To $4.87M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.39) by 56.41 percent. This is a 64.86 percent decrease over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $15.90 million which beat the analyst consensus estimate of $4.87 million by 226.41 percent. This is a 467.31 percent increase over sales of $2.80 million the same period last year.